Comparative Pharmacology
Head-to-head clinical analysis: CRYSVITA versus FASENRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRYSVITA versus FASENRA.
CRYSVITA vs FASENRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fibroblast growth factor 23 (FGF23) inhibitor; increases renal phosphate reabsorption and 1,25-dihydroxyvitamin D production by blocking FGF23 activity.
Benralizumab is a humanized afucosylated monoclonal antibody that binds to the alpha subunit of the interleukin-5 receptor (IL-5Rα) expressed on eosinophils and basophils. This binding inhibits IL-5-mediated signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in rapid and near-complete depletion of eosinophils from blood and tissues.
1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.
30 mg subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
None Documented
None Documented
16.4 days (terminal elimination half-life); supports monthly subcutaneous dosing.
Terminal half-life approximately 25 days (range 24–27 days), supporting every-4-week subcutaneous dosing.
Renal (minimal, as intact antibody); catabolized into small peptides and amino acids; no biliary/fecal elimination of intact drug.
Degraded into small peptides and amino acids via general protein catabolism; no significant renal or biliary/fecal excretion of intact drug.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody, Anti-Interleukin-5 Receptor